Molecure S.A. Market Cap ($32.77 Million)
Market Cap & Net Worth: Molecure S.A. (MOC)
Molecure S.A. market cap. Molecure S.A. (WAR:MOC) has a market capitalization of $32.77 Million (zł119.09 Million) as of November 1, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #23258 globally and #224 in its home market, demonstrating a -3.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Molecure S.A.'s stock price zł5.78 by its total outstanding shares 20603155 (20.60 Million). Also see Molecure S.A. (MOC) cash flow conversion for how efficiently the company converts equity into cash flow.
Molecure S.A. Market Cap History (2018–2026)
Molecure S.A. market cap history from 2018 to 2026. Data shows change from $81.09 Million to $32.77 Million (-17.22% CAGR). Check current stock price of Molecure S.A. for real-time trading data and today's change.
Molecure S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Molecure S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MOC shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
19.62x
Molecure S.A.'s market cap is 19.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $81.09 Million | $3.00K | -$3.78 Million | 27028.36x | N/A |
| 2019 | $55.46 Million | $2.81K | -$4.16 Million | 19756.11x | N/A |
| 2020 | $286.92 Million | $122.94 Million | $67.96 Million | 2.33x | 4.22x |
| 2021 | $212.07 Million | $400.00 | -$13.64 Million | 530171.67x | N/A |
| 2022 | $80.86 Million | $7.51 Million | -$13.54 Million | 10.76x | N/A |
| 2023 | $110.57 Million | $100.00 | -$28.37 Million | 1105705.63x | N/A |
| 2024 | $57.27 Million | $2.92 Million | -$31.29 Million | 19.62x | N/A |
Competitor Companies of MOC by Market Capitalization
Companies near Molecure S.A. in the global market cap rankings as of November 1, 2026. Also see MOC asset base for a full breakdown of the balance sheet.
Key companies related to Molecure S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Molecure S.A. (2018–2026)
Market capitalization of Molecure S.A. from 2018 to today. Between 2018 and today, Molecure S.A.'s market cap moved from $81.09 Million to $ 32.77 Million, with a yearly change of -17.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł32.77 Million | -12.42% |
| 2025 | zł37.42 Million | -34.65% |
| 2024 | zł57.27 Million | -48.21% |
| 2023 | zł110.57 Million | +36.75% |
| 2022 | zł80.86 Million | -61.87% |
| 2021 | zł212.07 Million | -26.09% |
| 2020 | zł286.92 Million | +417.38% |
| 2019 | zł55.46 Million | -31.61% |
| 2018 | zł81.09 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Molecure S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.77 Million USD |
| MoneyControl | $32.77 Million USD |
| MarketWatch | $32.77 Million USD |
| marketcap.company | $32.77 Million USD |
| Reuters | $32.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more